Compare ALEMBIC with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs BIOCON - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC BIOCON ALEMBIC/
BIOCON
 
P/E (TTM) x 74.5 31.8 234.2% View Chart
P/BV x 6.4 3.8 169.5% View Chart
Dividend Yield % 0.2 0.3 61.2%  

Financials

 ALEMBIC   BIOCON
EQUITY SHARE DATA
    ALEMBIC
Mar-18
BIOCON
Mar-19
ALEMBIC/
BIOCON
5-Yr Chart
Click to enlarge
High Rs72707 10.2%   
Low Rs34554 6.1%   
Sales per share (Unadj.) Rs4.791.9 5.1%  
Earnings per share (Unadj.) Rs6.116.7 36.5%  
Cash flow per share (Unadj.) Rs6.224.2 25.8%  
Dividends per share (Unadj.) Rs0.201.00 20.0%  
Dividend yield (eoy) %0.40.2 238.2%  
Book value per share (Unadj.) Rs40.7101.6 40.0%  
Shares outstanding (eoy) m267.03600.00 44.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.36.9 164.2%   
Avg P/E ratio x8.737.7 23.0%  
P/CF ratio (eoy) x8.526.1 32.5%  
Price / Book Value ratio x1.36.2 21.0%  
Dividend payout %3.36.0 54.8%   
Avg Mkt Cap Rs m14,139378,330 3.7%   
No. of employees `000NA6.1 0.0%   
Total wages/salary Rs m20711,653 1.8%   
Avg. sales/employee Rs ThNM8,994.3-  
Avg. wages/employee Rs ThNM1,900.7-  
Avg. net profit/employee Rs ThNM1,635.3-  
INCOME DATA
Net Sales Rs m1,25555,144 2.3%  
Other income Rs m3701,444 25.6%   
Total revenues Rs m1,62556,588 2.9%   
Gross profit Rs m11115,883 0.7%  
Depreciation Rs m384,478 0.8%   
Interest Rs m2709 0.2%   
Profit before tax Rs m44212,140 3.6%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m242,123 1.1%   
Profit after tax Rs m1,63010,026 16.3%  
Gross profit margin %8.928.8 30.7%  
Effective tax rate %5.417.5 31.0%   
Net profit margin %129.818.2 714.2%  
BALANCE SHEET DATA
Current assets Rs m1,86748,228 3.9%   
Current liabilities Rs m59130,376 1.9%   
Net working cap to sales %101.632.4 314.0%  
Current ratio x3.21.6 198.9%  
Inventory Days Days9468 138.0%  
Debtors Days Days7486 86.0%  
Net fixed assets Rs m1,79164,130 2.8%   
Share capital Rs m5343,000 17.8%   
"Free" reserves Rs m10,32457,980 17.8%   
Net worth Rs m10,85860,980 17.8%   
Long term debt Rs m4115,766 0.3%   
Total assets Rs m11,591121,924 9.5%  
Interest coverage x260.918.1 1,439.5%   
Debt to equity ratio x00.3 1.5%  
Sales to assets ratio x0.10.5 23.9%   
Return on assets %14.18.8 159.9%  
Return on equity %15.016.4 91.3%  
Return on capital %15.216.8 90.7%  
Exports to sales %1.528.1 5.5%   
Imports to sales %21.018.9 111.3%   
Exports (fob) Rs m1915,506 0.1%   
Imports (cif) Rs m26310,399 2.5%   
Fx inflow Rs m1915,506 0.1%   
Fx outflow Rs m26410,399 2.5%   
Net fx Rs m-2445,107 -4.8%   
CASH FLOW
From Operations Rs m23611,546 2.0%  
From Investments Rs m-224-7,138 3.1%  
From Financial Activity Rs m-27-2,417 1.1%  
Net Cashflow Rs m-152,103 -0.7%  

Share Holding

Indian Promoters % 64.0 40.4 158.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.2 8.4 2.4%  
FIIs % 9.7 10.7 90.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 19.9 131.2%  
Shareholders   54,701 109,995 49.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   PROCTER & GAMBLE HEALTH  CIPLA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 12, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS